Tensha Bags $15M Financing For Bromodomain Inhibitors
By Marie Powers
Tuesday, September 13, 2011
Tensha Therapeutics, a start-up developing small-molecule bromodomain inhibitors to treat cancer by regulating the transcription of disease-associated genes, has raised $15 million in a Series A financing from HealthCare Ventures LLC, of Boston.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.